Chronic Lymphocytic Leukemia - Alberta Health Services

CLINICAL PRACTICE GUIDELINE LYHE-007
Version 2
six months of treatment are identified as having refractory disease. Those demonstrating PD more than
six months after treatment has ended, who have previously achieved a CR or PR, are identified as having
relapsed disease. (3)
Table 3. Criteria for Identifying Treatment Response (3)
Parameter Complete response Partial response Progressive disease
(CR)
(PR)
(PD)
Lymphadenopathy None >1.5 cm Decrease ≥50% Increase ≥50% or
appearance of any new
lesion
Liver and/or spleen
size
Constitutional
symptoms
Polymorphonuclear
leukocytes
Normal size Decrease ≥50% Increase ≥50% or new
enlargement when
previously normal
None Any Any Any
>1.5 x 10 9 /L without
need for exogenous
growth factors
>1.5 x 10 9 /L or >50%
improvement over
baseline without need for
exogenous growth factors
Circulating clonal B- None Decrease ≥50% over
lymphocytes
baseline
Platelet count >100 x 10 9 /L without >100 x 10
need for exogenous
growth factors
9 /L or increase
≥50% over baseline
Hemoglobin >110 g/L (untransfused >110 g/L or increase
and without need for
exogenous
erythropoietin)
≥50% over baseline
Marrow Normocellular for age, No BM requirements to